Cancer Diagnostics Market to Reach US$ 76.8 Bn by 2026

1. Healthcare, Pharmaceuticals & Medical Devices May 2017 Report Id : REP-GB-1090 Status : Publish Category : Healthcare, Pharmaceuticals & Medical Devices ©2015 Future Market Insights, All Rights Reserved

2. About Future Market Insights Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights,aerial view of the competitiveframework,and future markettrends. We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology,Healthcare, and Retail. We have a global presence with delivery centers across India specializing in providing global research reports and country research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning from every corner of the world to distill it to one thing– the perfect solutionfor our client. Research Capabilities Sector Coverage             Customized Research Syndicated Research Investment Research Social Media Research Automotive and Transportation Electronics, Semiconductor, and ICT Retail and Consumer Products Industrial Automation and Equipment Chemicals & Materials Food and Beverages Services and Utilities Energy, Mining, Oil, and Gas Customized Research Subscription Information Syndicated Research For detailed subscription information please contact Hari. T (Sr. Manager - Global Business Development) Investment Research T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268 Email: hari.t@futuremarketinsights.com Social Media Research ©2015 Future Market Insights, All Rights Reserved 2

3. Research Methodology (1/2) Systematic Research Approach 1 In-depth secondary research is used to ascertain overall market size, top industry players, top products, industry associations, etc. Research & Intelligence Data Collection Data Filter & Analysis Actionable Insights Business Solution Market profiling 2 PMR formulates a detailed discussion guide to conduct expert and industry interviews     Identifying key opinion leaders Questionnaire design In-depth interviews Coverage across value chain Formulating discussion guide 3 A PMR develops a list of industry players (manufacturers), distributors, retailers and industry experts Primary Research       Key industry experts Channel study Developments Market dynamics Products Conclusions Developing list of respondents B 4 PMR conducts interviews with industry experts, industry players, distributors and retailers SOLUTION Desk Research Data collection      Market participants Key strengths Product portfolio Mapping as per value chain Key focus segments C Company Analysis Data is validated by triangulation method, wherein secondary, primary and PMR analysis contribute to the final data 5 Data validation 6 Data is scrutinized using MS-Excel to obtain qualitative and quantitative insights about the industry Data analysis Primary Research# Secondary Research # Paid Publications#           Linkedin Zoominfo Salesforce Avention Company websites Company annual reports White papers Financial reports Factiva GBI Genios Meltwater 7 PMR delivers industry insights and information in the required format (PDF) Insights   # includes sources of databases ©2015 Future Market Insights, All Rights Reserved 3

4. Cancer Diagnostics Market Analysis Biotechnology companies are focusing on the development of genotype- and phenotype-specific drugs for chronic diseases such as cancer in order to ensure that next-generation drugs are more efficacious. Multiplex and multi-analyte biomarkers play an important role in the development of translational medicine, which facilitates the translation of basic research into medical advances. In line with this, most pharmaceutical and biotechnology companies are committing to associate their drugs with diagnostic assays, as a number of multiplex biomarkers are directly associated with particular drugs. The growing research and development activities in cancer diagnostics are thus expected to bring revolutionary technologies in cancer diagnostics and in turn would drive the growth of the cancer diagnostics market. Future Market Insights, in its latest report on cancer diagnostics, estimates that the global market for cancer diagnostics is expected to expand 2.3x in terms of revenue by 2026 over 2016 and is estimated to reach US$ 76.8 Bn by 2026 end. Cancer Diagnostics Market: Overview & Global Market Scenario Early detection of cancer requires suitable cancer diagnostics procedures to screen the asymptomatic population that is on average risk of cancer, particularly for breast cancer, cervical cancers, colon cancers and melanoma. Increasing awareness towards the early signs and symptoms of cancer among physicians and other healthcare professionals as well as the general population. ©2015 Future Market Insights, All Rights Reserved 4

5. Cancer Diagnostics Market Analysis Early detection of cancer requires suitable cancer diagnostics procedures to screen the asymptomatic population that is on average risk of cancer, particularly for breast cancer, cervical cancers, colon cancers and melanoma. Increasing awareness towards the early signs and symptoms of cancer among physicians and other healthcare professionals as well as the general population. Request Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1090 Next generation sequencing (NGS) is the most cost-effective, time saving and successful technological advancement in cancer diagnostics in the last three decades. Revolutionary second-generation and third platforms for cancer diagnostics offered by Roche, Illumina and Life Technologies, Pacific Biosciences of California, Inc. are rapidly gaining adoption in the cancer diagnostics market. Many molecular pathology laboratories are transitioning from single molecular PCR protocols to NGS platforms and thus, the market for cancer diagnostics is expected to gain traction. However, despite the high value propositions of molecular diagnostics for cancer diagnosis, insufficient coverage for costly test procedures discourages majority of patients from pursuing these tests. Moreover, according to the new pricing policy for 2017, CMS has increased rates for several new CPT codes including next-gen sequencing and multi analyte algorithm assays. ©2015 Future Market Insights, All Rights Reserved 5

6. Cancer Diagnostics Market Analysis For instance, CMS increased the cost of next-generation sequencing tests for hereditary breast cancer- related disorders (CPT code 81432) from US$ 623 to US$ 925. It is anticipated that state Medicaid programs will also adjust their prices to reflect Medicare rates. Regulators of CMS as well as private payers are increasingly emphasizing on increasing value and single-source tests having strong evidence of clinical utility. In 2013, CMS discontinued the ‘code stacking’ method for molecular diagnostic reimbursement for cancer. The center has dissolved this policy due to the wrongful exploitation of payment scheme by some of the labs and has stopped paying bills for these tests until the new method of ‘market-based pricing’ comes into action by 2018. The biopsy segment is likely to dominate the global cancer diagnostics market, primarily due to the introduction of new and advanced techniques such as liquid biopsy and fine needle aspiration for lung cancer. However, the imaging cancer diagnostics segment is expected to gain significant traction due to the high efficiency of imaging technologies such as PET/CT. Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-1090 ©2015 Future Market Insights, All Rights Reserved 6

7. Cancer Diagnostics Market Analysis Cancer Diagnostics Market: Competitive Analysis The competition landscape in the global cancer diagnostics market is changing rapidly. Although molecular testing is a hotspot for investment in in vitro diagnostics, the market exhibits awfully delayed growth due to slow returns on investment. In spite of this, all big cancer diagnostics players in the global market are continuously investing in cancer diagnostics, including molecular biomarker testing, NGS, PET scanners, etc. Companies are also investing in the automation of existing molecular assays for cancer diagnostics to foster future growth prospects in the cancer diagnostics market; however, due to the strong competition among companies in the cancer diagnostics market, they may confront price erosion. For instance, Roche, in spite of being a global leader in cancer diagnostics for many years, has lost some ground after huge investments by its global peers such as Thermo Fisher Scientific Inc. and Merck KGaA, among others. Click here to Order a free sample ©2015 Future Market Insights, All Rights Reserved 7

8. To know more about us, please visit our website: www.futuremarketinsights.com For sales queries or new topics email us on: sales@futuremarketinsights.com For media queries, contact the press office at press@futuremarketinsights.com For other queries contact: Hari. T (Sr. Manager - Global Business Development) Future Market Insights: 3rd Floor, 207 Regent Street, London W1B 3HH T: +44 20 7692 8790 | D: +44 20 3287 4268 Email: hari.t@futuremarketinsights.com Future Market Insights Global & Consulting Private Limited (FMI) Thank You ©2015 Future Market Insights, All Rights Reserved 8